Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3546 |
|
| Actual shortage: | 240 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3292 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DORZO-TIMOP | 5MG 20MG | SOLUTION SOLUTION | Resolved | 2025-02-06 | 2025-03-21 | 249755 |
| APO-DORZO-TIMOP | 5MG 20MG | SOLUTION SOLUTION | Resolved | 2025-05-08 | 2025-06-06 | 256920 |
| APO-DORZO-TIMOP | 20MG 5MG | SOLUTION SOLUTION | Resolved | 2025-11-13 | 2025-11-28 | 271862 |
| APO-DOXAZOSIN | 4MG | TABLET | Resolved | 2018-01-22 | 2018-07-03 | 36812 |
| APO-DOXAZOSIN | 4MG | TABLET | Resolved | 2020-02-05 | 2020-04-01 | 105323 |
| APO-DOXAZOSIN | 2MG | TABLET | Resolved | 2020-07-23 | 2020-11-16 | 120982 |
| APO-DOXAZOSIN | 1MG | TABLET | Resolved | 2023-02-09 | 2023-03-23 | 184077 |
| APO-DOXAZOSIN | 2MG | TABLET | Resolved | 2023-02-23 | 2023-03-23 | 185451 |
| APO-DOXAZOSIN | 4MG | TABLET | Resolved | 2023-12-08 | 2024-03-22 | 212946 |
| APO-DOXAZOSIN | 2MG | TABLET | Resolved | 2025-05-15 | 2025-06-27 | 257397 |
| APO-DOXAZOSIN | 1MG | TABLET | Resolved | 2025-05-22 | 2025-07-18 | 258169 |
| APO-DOXAZOSIN | 4MG | TABLET | Resolved | 2025-12-04 | 2025-12-19 | 273333 |
| APO-DOXEPIN | 10MG | CAPSULE | Resolved | 2017-03-10 | 2017-04-03 | 294 |
| APO-DOXEPIN | 100MG | CAPSULE | Resolved | 2017-03-10 | 2017-04-03 | 298 |
| APO-DOXEPIN | 25MG | CAPSULE | Resolved | 2017-03-10 | 2017-04-10 | 302 |
| APO-DOXEPIN | 50MG | CAPSULE | Resolved | 2017-03-27 | 2017-04-03 | 4389 |
| APO-DOXEPIN | 10MG | CAPSULE | Resolved | 2017-06-19 | 2017-07-04 | 13312 |
| APO-DOXEPIN | 150MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19003 |
| APO-DOXEPIN | 10MG | CAPSULE | Resolved | 2017-11-07 | 2017-12-08 | 28546 |
| APO-DOXEPIN | 25MG | CAPSULE | Resolved | 2017-11-21 | 2017-12-08 | 29957 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |